Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-24T11:11:23.456Z Has data issue: false hasContentIssue false

64 - Antiviral therapy of HSV-1 and -2

from Part VI - Antiviral therapy

Published online by Cambridge University Press:  24 December 2009

By
David W. Kimberlin  and
Richard J. Whitley
Edited by
Ann Arvin ,
Gabriella Campadelli-Fiume ,
Edward Mocarski ,
Patrick S. Moore ,
Bernard Roizman ,
Richard Whitley  and
Koichi Yamanishi
David W. Kimberlin
Affiliation:
Department of Pediatrics, University of Alabama at Birmingham, AL, USA
Richard J. Whitley
Affiliation:
Department of Pediatrics, University of Alabama at Birmingham, AL, USA
Ann Arvin
Affiliation:
Stanford University, California
Gabriella Campadelli-Fiume
Affiliation:
Università degli Studi, Bologna, Italy
Edward Mocarski
Affiliation:
Emory University, Atlanta
Patrick S. Moore
Affiliation:
University of Pittsburgh
Bernard Roizman
Affiliation:
University of Chicago
Richard Whitley
Affiliation:
University of Alabama, Birmingham
Koichi Yamanishi
Affiliation:
University of Osaka, Japan
Get access

Summary

Introduction

The discovery of effective antiviral agents has been facilitated by advances in the fields of molecular biology and virology. In the pre-antiviral era, the widely held belief was that any therapeutically meaningful interference with viral replication would destroy the host cell upon which viral replication was dependent. A growing understanding of host cell–virus interactions and viral replication, however, has led to the development of safe and effective antivirals. These agents act by impeding entry of viruses into host cells; interfering with viral assembly, release, or de-aggregation; inhibiting transcription or replication of the viral genome; or interrupting viral protein synthesis.

Antiviral agents can be used to treat disease (a therapeutic strategy), to prevent infection (a prophylactic strategy), or to prevent disease (a preemptive strategy). Prophylaxis refers to the administration of an agent to patients at risk of contracting infection (e.g., acyclovir given to HSV-seropositive renal transplant recipients). Pre-emptive treatment refers to the administration of a drug after there is evidence of infection, but before there is evidence of disease (e.g., ganciclovir given to bone marrow transplant recipients with positive CMV culture, but no symptoms of infection).

The effectiveness of antiviral therapy sometimes is limited by the development of antiviral resistance. Antiviral drug resistance has increased in parallel with the expanded use of, and indications for, antiviral therapy. Resistance most commonly occurs in patients with chronic and/or progressive infections who have been exposed to prolonged or repeated courses of therapy.

Type
Chapter
Information
Human Herpesviruses
Biology, Therapy, and Immunoprophylaxis
 , pp. 1153 - 1174
Publisher: Cambridge University Press
Print publication year: 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alexander, L. and Naisbett, B. (2002). Patient and physician partnerships in managing genital herpes. J. Infect. Dis., 186, S57–65.CrossRefGoogle ScholarPubMed
American Academy of Pediatrics (2003). Herpes simplex. In 2003 Red Book: Report of the Committee on Infectious Diseases, ed. Pickering, L. K.American Academy of Pediatrics, Elk Grove Village, IL, pp. 344–353.Google Scholar
Anonymous (2002). Sexually transmitted diseases treatment guidelines 2002. Morb. Mortal. Wkly Rep., 51, RR-6, 12–17.
Aoki, F. Y., Law, B. J., Hammond, G. W. et al. and The Acyclovir-Gingivostomatitis Research Group (1993). Acyclovir (ACV) suspension for treatment of acute herpes simplex virus (HSV) gingivostomatitis in children: a placebo(PL) controlled, double blind trial. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA, p. 399, Abstract #1530.
Baker, D. and Eisen, D. (2003). Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis., 71, 239–242.Google ScholarPubMed
Baker, D. A., Deeter, R. G., Redder, K., and Phillips, J. A. (2000). Valacyclovir effective for suppression of recurrent HSV-1 herpes labialis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, p. 263, Abstract #464.
Bell, W. R., Chulay, J. D., and Feinberg, J. E. (1997). Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine, 76, 369–380.CrossRefGoogle Scholar
Benedetti, J., Corey, L., and Ashley, R. (1994). Recurrence rates in genital herpes after symptomatic first-episode infection. Ann. Intern. Med., 121, 847–854.CrossRefGoogle ScholarPubMed
Bodsworth, N. J., Crooks, R. J., Borelli, S.et al. and the International Valaciclovir HSV Study Group (1997). Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin. Med., 73, 110–116.Google ScholarPubMed
Boike, S. C., Pue, M. A., Freed, M. I.et al. (1994). Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin. Pharmacol. Ther., 55, 418–426.CrossRefGoogle ScholarPubMed
Boon, R., Goodman, J. J., Martinez, J., Marks, G. L., Gamble, M., and Welch, C. (2000). Penciclovir cream for the treatment of sunlight-induced herpes simplex labialis: a randomized, double-blind, placebo-controlled trial. Penciclovir Cream Herpes Labialis Study Group. Clin. Ther., 22, 76–90.CrossRefGoogle ScholarPubMed
Brown, F., Banken, L., Saywell, K., and Arum, I. (1999). Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Pharmacokinet., 37, 167–176.CrossRefGoogle ScholarPubMed
Bryson, Y. J., Dillon, M., Lovett, M.et al. (1983). Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N. Engl. J. Med., 308, 916–921.CrossRefGoogle ScholarPubMed
Chosidow, O., Drouault, Y., Leconte-Veyriac, F.et al. (2001). Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Br. J. Dermatol., 144, 818–824.CrossRefGoogle ScholarPubMed
Chosidow, O., Drouault, Y., Garraffo, R., Veyssier, P., and Valaciclovir Herpes Facialis Study, G. (2003). Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial. Br. J. Dermatol., 148, 142–146.CrossRefGoogle ScholarPubMed
Cocohoba, J. M. and McNicholl, I. R. (2002). Valganciclovir: an advance in cytomegalovirus therapeutics. Ann. Pharmacother., 36, 1075–1079.CrossRefGoogle ScholarPubMed
Corey, L., Nahmias, A. J., Guinan, M. E., Benedetti, J. K., Critchlow, C. W., and Holmes, K. K. (1982). A trial of topical acyclovir in genital herpes simplex virus infections. N. Engl. J. Med., 306, 1313–1319.CrossRefGoogle ScholarPubMed
Corey, L., Wald, A., Patel, R.et al. and the Valacyclovir HSV Transmission Study Group (2004). Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med., 350, 11–20.CrossRefGoogle ScholarPubMed
Cundy, K. C., Petty, B. G., Flaherty, J.et al. (1995). Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 39, 1247–1252.CrossRefGoogle ScholarPubMed
Deray, G., Martinez, F., Katlama, C.et al. (1989). Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am. J. Nephrol., 9, 316–321.CrossRefGoogle Scholar
Diaz-Mitoma, F., Sibbald, R. G., Shafran, S. D., Boon, R., Saltzman, R. L., and the Collaborative Famciclovir Genital Herpes Research Group (1998). Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. J. Am. Med. Assoc., 280, 887–892.CrossRefGoogle ScholarPubMed
Douglas, J. M., Critchlow, C., Benedetti, J.et al. (1984). A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N. Engl. J. Med., 310, 1551–1556.CrossRefGoogle ScholarPubMed
Drew, W. L., Ives, D., Lalezari, J. P.et al. and the Syntex Cooperative Oral Ganciclovir Study Group (1995). Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. N. Engl. J. Med., 333, 615–620.CrossRefGoogle ScholarPubMed
Drew, W. L., Stempien, M. J., Andrews, J.et al. (1999). Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J. Infect. Dis., 179, 1352–1355.CrossRefGoogle ScholarPubMed
Elion, G. B. (1982). Mechanism of action and selectivity of acyclovir. Am. J. Med., 73, 7–13.CrossRefGoogle ScholarPubMed
Englund, J. A., Zimmerman, M. E., Swierkosz, E. M., Goodman, J. L., Scholl, D. R., and Balfour, H. H. Jr. (1990). Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann. Intern. Med., 112, 416–422.CrossRefGoogle Scholar
Englund, J. A., Fletcher, C. V., and Balfour, H. H. Jr. (1991). Acyclovir therapy in neonates. J. Pediatr., 119, 129–135.CrossRefGoogle ScholarPubMed
Field, A. K. and Biron, K. K. (1994). The end of innocence revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev., 7, 1–13.CrossRefGoogle ScholarPubMed
Fife, K. H., Barbarash, R. A., Rudolph, T., Degregorio, B., Roth, R., and the Valaciclovir International Herpes Simplex Virus Study Group (1997). Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. Sexually Transm. Dis., 24, 481–486.CrossRefGoogle ScholarPubMed
Fletcher, C., Sawchuk, R., Chinnock, B., Miranda, P., and Balfour, H. H. Jr. (1986). Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther., 40, 281–286.CrossRefGoogle ScholarPubMed
Frenkel, L. M., Capparelli, E. V., Dankner, W. M.et al. and The Pediatric AIDS Clinical Trials Group (2000). Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. J. Infect. Dis., 182, 1616–1624.CrossRefGoogle ScholarPubMed
Gateley, A., Gander, R. M., Johnson, P. C., Kit, S., Otsuka, H., and Kohl, S. (1990). Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J. Infect. Dis., 161, 711–715.CrossRefGoogle Scholar
Gibson, J. R., Klaber, M. R., Harvey, S. G., Tosti, A., Jones, D., and Yeo, J. M. (1986). Prophylaxis against herpes labialis with acyclovir cream – a placebo-controlled study. Dermatologica, 172, 104–107.CrossRefGoogle Scholar
Gold, D. and Corey, L. (1987). Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob. Agents Chemother., 31, 361–367.CrossRefGoogle ScholarPubMed
Goldberg, L. H., Kaufman, R., Kurtz, T. O.et al. (1993). Long-term suppression of recurrent genital herpes with acyclovir. A 5-year benchmark. Acyclovir Study Group. Arch. Dermatol., 129, 582–587.CrossRefGoogle ScholarPubMed
Herpetic Eye Disease Study Group (1998). Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N. Engl. J. Med., 339, 300–306.CrossRef
Herpetic Eye Disease Study Group (2000). Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Arch. Ophthalmol., 118, 1030–1036.CrossRef
Ho, H. T., Woods, K. L., Bronson, J. J., Boeck, H., Martin, J. C., and Hitchcock, M. J. (1992). Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol., 41, 197–202.Google ScholarPubMed
Hovding, G. (1989). A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial. Acta Ophthalmol., 67, 51–54.CrossRefGoogle ScholarPubMed
Jacobson, M. A. (1993). Valaciclovir (BW256U87): the L-valyl ester of acyclovir. J. Med. Virol., Suppl, 150–153.CrossRefGoogle ScholarPubMed
Jacobson, M. A., Miranda, P., Cederberg, D. M.et al. (1987). Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Chemother., 31, 1251–1254.CrossRefGoogle ScholarPubMed
Jung, D. and Dorr, A. (1999). Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J. Clin. Pharmacol., 39, 800–804.CrossRefGoogle ScholarPubMed
Kimberlin, D. W. (2001). Advances in the treatment of neonatal herpes simplex infections. Rev. Med. Virol., 11, 157–163.CrossRefGoogle ScholarPubMed
Kimberlin, D. W. and Prober, C. G. (2003). Antiviral agents. In Principles and Practice of Pediatric Infectious Diseases, ed. Long, S. S., Pickering, L. K., and Prober, C. G.Philadelphia: Churchill Livingstone, pp. 1527–1547.Google Scholar
Kimberlin, D. W. and Rouse, D. J. (2004). Genital herpes. N. Engl. J. Med., 350(19), 1970–1977.CrossRefGoogle ScholarPubMed
Kimberlin, D. W., Coen, D. M., Biron, K. K.et al. (1995a). Molecular mechanisms of antiviral resistance. Antiviral Res., 26, 369–401.CrossRefGoogle Scholar
Kimberlin, D. W., Crumpacker, C. S., Straus, S. E.et al. (1995b). Antiviral resistance in clinical practice. Antiviral Res., 26, 423–438.CrossRefGoogle Scholar
Kimberlin, D., Powell, D., Gruber, W.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1996a). Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr. Infect. Dis. J., 15, 247–254.CrossRefGoogle Scholar
Kimberlin, D. W., Lakeman, F. D., Arvin, A. M.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1996b). Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J. Infect. Dis., 174, 1162–1167.CrossRefGoogle Scholar
Kimberlin, D. W., Lin, C. Y., Jacobs, R. F.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2001a). Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics, 108, 230–238.CrossRefGoogle Scholar
Kimberlin, D. W., Lin, C. Y., Jacobs, R. F.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (2001b). Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics, 108, 223–229.CrossRefGoogle Scholar
Kost, R. G., Hill, E. L., Tigges, M., and Straus, S. E. (1993). Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N. Engl. J. Med., 329, 1777–1782.CrossRefGoogle Scholar
Krasny, H. C., Liao, S. H., Miranda, P., Laskin, O. L., Whelton, A., and Lietman, P. S. (1982). Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. Am. J. Med., 73, 202–204.CrossRefGoogle ScholarPubMed
Kuppermann, B. D., Quiceno, J. I., Flores-Aguilar, M.et al. (1993). Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J. Infect. Dis., 168, 1506–1509.CrossRefGoogle ScholarPubMed
Lalezari, J. P., Drew, W. L., Glutzer, E.et al. (1994). Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J. Infect. Dis., 170, 570–572.CrossRefGoogle Scholar
Lalezari, J. P., Drew, W. L., Glutzer, E.et al. (1995). (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis., 171, 788–796.CrossRefGoogle ScholarPubMed
Lalezari, J. P., Stagg, R. J., Kuppermann, B. D.et al. (1997). Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med., 126, 257–263.CrossRefGoogle ScholarPubMed
Laskin, O. L., Longstreth, J. A., Whelton, A.et al. (1982). Effect of renal failure on the pharmacokinetics of acyclovir. Am. J. Med., 73, 197–201.CrossRefGoogle ScholarPubMed
Leone, P. A., Trottier, S., and Miller, J. M. (2002). Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin. Infect. Dis., 34, 958–962.CrossRefGoogle ScholarPubMed
Lin, L., Chen, X. S., Cui, P. G.et al. and Topical Penciclovir Clinical Study, G. (2002). Topical application of penciclovir cream for the treatment of herpes simplex facialis/labialis: a randomized, double-blind, multicentre, aciclovir-controlled trial. J. Dermatol. Treatm., 13, 67–72.CrossRefGoogle ScholarPubMed
Loveless, M., Harris, W., and Sacks, S. (1995). Treatment of first episode genital herpes with famciclovir. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; Abstract H12, Abstract H12.
Luby, J. P., Gnann, J. W. Jr., Alexander, W. J.et al. (1984). A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. J. Infect. Dis., 150, 1–6.CrossRefGoogle ScholarPubMed
Lyall, E. G., Ogilvie, M. M., Smith, N. M., and Burns, S. (1994). Acyclovir resistant varicella zoster and HIV infection. Arch. Dis. Child., 70, 133–135.CrossRefGoogle ScholarPubMed
MacGregor, R. R., Graziani, A. L., Weiss, R., Grunwald, J. E., and Gambertoglio, J. G. (1991). Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. J. Infect. Dis., 164, 785–787.Google Scholar
Markham, A. and Faulds, D. (1994). Ganciclovir. an update of its therapeutic use in cytomegalovirus infection. Drugs, 48, 455–484.CrossRefGoogle ScholarPubMed
Martin, D. F., Sierra-Madero, J., Walmsley, S.et al. and the Valganciclovir Study Group (2002). A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med., 346, 1119–1126.CrossRefGoogle ScholarPubMed
Mertz, G. J., Critchlow, C. W., Benedetti, J.et al. (1984). Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. J. Am. Med. Assoc., 252, 1147–1151.CrossRefGoogle ScholarPubMed
Mertz, G. J., Eron, L., Kaufman, R.et al. (1988a). Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am. J. Med., 85, 14–19.Google Scholar
Mertz, G. J., Jones, C. C., Mills, J.et al. (1988b). Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial. J. Am. Med. Assoc., 260, 201–206.CrossRefGoogle Scholar
Mertz, G. J., Loveless, M. O., Levin, M. J.et al. and the Collaborative Famciclovir Genital Herpes Research Group (1997a). Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Arch. Intern. Med., 157, 343–349.CrossRefGoogle Scholar
Mertz, G. J., Loveless, M. O., Levin, M. J.et al. and the Collaborative Famciclovir Genital Herpes Research Group (1997b). Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Arch. Intern. Med., 157, 343–349.CrossRefGoogle Scholar
Meyers, J. D., Wade, J. C., Mitchell, C. D.et al. (1982). Multicenter collaborative trial of intravenous acyclovir for treatment of mucocutaneous herpes simplex virus infection in the immunocompromised host. Am. J. Med., 73, 229–235.CrossRefGoogle ScholarPubMed
Mindel, A., Faherty, A., Carney, O., Patou, G., Freris, M., and Williams, P. (1988). Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet., 1, 926–928.CrossRefGoogle ScholarPubMed
Morfin, F. and Thouvenot, D. (2003). Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol., 26, 29–37.CrossRefGoogle ScholarPubMed
Nadal, D., Leverger, G., Sokal, E. M.et al. (2002). An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J. Infect. Dis., 186, S123–S130.CrossRefGoogle ScholarPubMed
Nilsen, A. E., Aasen, T., Halsos, A. M.et al. (1982). Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet, 2, 571–573.CrossRefGoogle ScholarPubMed
Patel, R., Bodsworth, N. J., Woolley, P.et al. and the International Valaciclovir HSV Study Group (1997). Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. Genitourin. Med., 73, 105–109.Google ScholarPubMed
Raborn, G. W., McGaw, W. T., Grace, M., Tyrrell, L. D., and Samuels, S. M. (1987). Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study. J. Am. Dent. Assoc., 115, 38–42.CrossRefGoogle ScholarPubMed
Raborn, G. W., McGaw, W. T., Grace, M., and Percy, J. (1988). Treatment of herpes labialis with acyclovir. Review of three clinical trials. Am. J. Med., 85, 39–42.Google ScholarPubMed
Raborn, G. W., Martel, A. Y., Grace, M. G., and McGaw, W. T. (1997). Herpes labialis in skiers: randomized clinical trial of acyclovir cream versus placebo. Oral Surg., Oral Med., Oral Pathol., Oral Radiol. Endodontics, 84, 641–645.CrossRefGoogle ScholarPubMed
Reardon, J. E. and Spector, T. (1989). Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J. Biol. Chem., 264, 7405–7411.Google ScholarPubMed
Reichman, R. C., Badger, G. J., Mertz, G. J.et al. (1984). Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. Jama., 251, 2103–2107.CrossRefGoogle ScholarPubMed
Reiff-Eldridge, R., Heffner, C. R., Ephross, S. A., Tennis, P. S., White, A. D., and Andrews, E. B. (2000). Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am. J. Obstet. Gyn., 182, 159–163.CrossRefGoogle ScholarPubMed
Reitano, M., Tyring, S., Lang, W.et al. and the International Valaciclovir HSV Study Group (1998). Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J. Infect. Dis., 178, 603–610.CrossRefGoogle ScholarPubMed
Revankar, S. G., Applegate, A. L., and Markovitz, D. M. (1995). Delirium associated with acyclovir treatment in a patient with renal failure. Clin. Infect. Dis., 21, 435–436.CrossRefGoogle Scholar
Rooney, J. F., Straus, S. E., Mannix, M. L.et al. (1993). Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann. Intern. Med., 118, 268–272.CrossRefGoogle ScholarPubMed
Ruhnek-Forsbeck, M., Sandstrom, E., Andersson, B.et al. (1985). Treatment of recurrent genital herpes simplex infections with oral acyclovir. J. Antimicrob. Chemother., 16, 621–628.CrossRefGoogle ScholarPubMed
Sacks, S. L., Aoki, F. Y., Diaz-Mitoma, F., Sellors, J., and Shafran, S. D. (1996a). Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. J. Am. Med. Assoc., 276, 44–49.CrossRefGoogle Scholar
Sacks, S. L., Aoki, F. Y., Diaz-Mitoma, F., Sellors, J., Shafran, S. D., and the Canadian Famciclovir Study Group (1996b). Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. J. Am. Med. Assoc., 276, 44–49.CrossRefGoogle Scholar
Sacks, S. L., Hughes, A., Rennie, B., and Boon, R. (1997). Famciclovir for suppression of asymptomatic and symptomatic recurrent genital herpes shedding: a randomized, double-blind, double-dummy, parallel-group, placebo-controlled trial. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada; Abstract H-73.
Safrin, S., Berger, T. G., Gilson, I.et al. (1991a). Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann. of Inter. Medi., 115, 19–21.CrossRefGoogle Scholar
Safrin, S., Crumpacker, C., Chatis, P.et al. and The AIDS Clinical Trials Group (1991b). A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N. Engl. J. Med., 325, 551–555.CrossRefGoogle Scholar
Safrin, S., Kemmerly, S., Plotkin, B.et al. (1994). Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J. Infect. Dis., 169, 193–196.CrossRefGoogle ScholarPubMed
Safrin, S., Cherrington, J., and Jaffe, H. S. (1999). Cidofovir. Review of current and potential clinical uses. Adv. Expe. Med. Biol., 458, 111–120.CrossRefGoogle ScholarPubMed
Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W., and Lietman, P. S. (1981). Acyclovir prophylaxis of herpes-simplex-virus infections. N. Engl. J. Med., 305, 63–67.CrossRefGoogle ScholarPubMed
Shaw, M., King, M., Best, J. M., Banatvala, J. E., Gibson, J. R., and Klaber, M. R. (1985). Failure of acyclovir cream in treatment of recurrent herpes labialis. Bri. Med. J. Clini. Res., 291, 7–9.CrossRefGoogle ScholarPubMed
Shepp, D. H., Newton, B. A., Dandliker, P. S., Flournoy, N., and Meyers, J. D. (1985). Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann. Inter. Med., 102, 783–785.CrossRefGoogle ScholarPubMed
Skoldenberg, B., Forsgren, M., Alestig, K.et al. (1984). Acyclovir versus vidarabine in herpes simplex encephalitis. Randomised multicentre study in consecutive Swedish patients. Lancet., 2, 707–711.CrossRefGoogle ScholarPubMed
Snoeck, R., Andrei, G., Gerard, M.et al. (1994). Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis., 18, 570–578.CrossRefGoogle Scholar
Soul-Lawton, J., Seaber, E., On, N., Wootton, R., Rolan, P., and Posner, J. (1995). Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob. Agents Chemother., 39, 2759–2764.CrossRefGoogle Scholar
Spector, S. A., Hsia, K., Wolf, D., Shinkai, M., and Smith, I. (1995). Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin. Infect. Dis., 21, S170–S173.CrossRefGoogle ScholarPubMed
Spruance, S. L., Crumpacker, C. S., Schnipper, L. E.et al. (1984). Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob. Agents Chemother., 25, 553–555.CrossRefGoogle ScholarPubMed
Spruance, S. L., Hamill, M. L., Hoge, W. S., Davis, L. G., and Mills, J. (1988). Acyclovir prevents reactivation of herpes simplex labialis in skiers. J. Am. Med. Assoc., 260, 1597–1599.CrossRefGoogle ScholarPubMed
Spruance, S. L., Stewart, J. C., Rowe, N. H., McKeough, M. B., Wenerstrom, G., and Freeman, D. J. (1990). Treatment of recurrent herpes simplex labialis with oral acyclovir. J. Infect. Dis., 161, 185–190.CrossRefGoogle ScholarPubMed
Spruance, S. L., Freeman, D. J., Stewart, J. C.et al. (1991). The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir. J. Infect. Dis., 163, 728–734.CrossRefGoogle ScholarPubMed
Spruance, S. L., Tyring, S. K., DeGregorio, B., Miller, C., Beutner, K., and the Valaciclovir HSV Study Group (1996). A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med., 156, 1729–1735.CrossRefGoogle ScholarPubMed
Spruance, S. L., Rea, T. L., Thoming, C., Tucker, R., Saltzman, R., and Boon, R. (1997). Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group. J. Am. Med. Assoc., 277, 1374–1379.CrossRefGoogle ScholarPubMed
Spruance, S. L., Nett, R., Marbury, T., Wolff, R., Johnson, J., and Spaulding, T. (2002). Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob. Agents Chemother., 46, 2238–2243.CrossRefGoogle ScholarPubMed
Spruance, S. L., Jones, T. M., Blatter, M. M.et al. (2003). High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob. Agents Chemother., 47, 1072–1080.CrossRefGoogle ScholarPubMed
Straus, S. E., Takiff, H. E., Seidlin, M.et al. (1984). Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N. Engl. J. Med., 310, 1545–1550.CrossRefGoogle ScholarPubMed
Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (1992). Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N. Engl. J. Med., 326, 213–220.CrossRef
Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (1997). Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann. Intern. Med., 126, 264–274.CrossRef
Swan, S. K., Munar, M. Y., Wigger, M. A., and Bennett, W. M. (1991). Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am. J. Kidney Dis., 17, 69–72.CrossRefGoogle Scholar
Trang, J. M., Kidd, L., Gruber, W.et al. and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1993). Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clin. Pharmacol. Ther., 53, 15–21.CrossRefGoogle ScholarPubMed
Tyring, S. K., Douglas, J. M. Jr., Corey, L., Spruance, S. L., Esmann, J., and the Valaciclovir International Study Group (1998). A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch. Dermatol., 134, 185–191.CrossRefGoogle ScholarPubMed
Wade, J. C., Newton, B., McLaren, C., Flournoy, N., Keeney, R. E., and Meyers, J. D. (1982). Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann. Intern. Med., 96, 265–269.CrossRefGoogle ScholarPubMed
Wade, J. C., McLaren, C., and Meyers, J. D. (1983). Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J. Infect. Dis., 148, 1077–1082.CrossRefGoogle ScholarPubMed
Wagstaff, A. J. and Bryson, H. M. (1994). Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs, 48, 199–226.CrossRefGoogle ScholarPubMed
Wagstaff, A. J., Faulds, D., and Goa, K. L. (1994). Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 47, 153–205.CrossRefGoogle ScholarPubMed
Wald, A., Benedetti, J., Davis, G., Remington, M., Winter, C., and Corey, L. (1994). A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections. Antimicrob. Agents Chemother., 38, 174–176.CrossRefGoogle ScholarPubMed
Wald, A., Zeh, J., Barnum, G., Davis, L. G., and Corey, L. (1996). Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann. Intern. Med., 124, 8–15.CrossRefGoogle ScholarPubMed
Wald, A., Corey, L., Cone, R., Hobson, A., Davis, G., and Zeh, J. (1997). Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Investig., 99, 1092–1097.CrossRefGoogle ScholarPubMed
Wald, A., Warren, T., Hu, H. et al. (1998). Suppression of subclinical shedding of herpes simplex virus type 2 in the genital tract with valaciclovir. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, California; Abstract H-82.
Wald, A., Carrell, D., Remington, M., Kexel, E., Zeh, J., and Corey, L. (2002). Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin. Infect. Dis., 34, 944–948.CrossRefGoogle ScholarPubMed
Weller, S., Blum, M. R., Doucette, M.et al. (1993). Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Ther., 54, 595–605.CrossRefGoogle ScholarPubMed
Whitley, R. J., Nahmias, A. J., Soong, S. J., Galasso, G. G., Fleming, C. L., and Alford, C. A. (1980a). Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics, 66, 495–501.Google Scholar
Whitley, R. J., Nahmias, A. J., Visintine, A. M., Fleming, C. L., and Alford, C. A. (1980b). The natural history of herpes simplex virus infection of mother and newborn. Pediatrics, 66, 489–494.Google Scholar
Whitley, R. J., Yeager, A., Kartus, P.et al. (1983). Neonatal herpes simplex virus infection: follow-up evaluation of vidarabine therapy. Pediatrics, 72, 778–785.Google ScholarPubMed
Whitley, R. J., Alford, C. A., Hirsch, M. S.et al. (1986). Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N. Engl. J. Med., 314, 144–149.CrossRefGoogle ScholarPubMed
Whitley, R. J., Corey, L., Arvin, A.et al. (1988). Changing presentation of herpes simplex virus infection in neonates. J. Infect. Dis., 158, 109–116.CrossRefGoogle ScholarPubMed
Whitley, R. J., Arvin, A., Prober, C.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1991a). A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N. Engl. J. Med., 324, 444–449.CrossRefGoogle Scholar
Whitley, R. J., Arvin, A., Prober, C.et al. and The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group (1991b). Predictors of morbidity and mortality in neonates with herpes simplex virus infections. N. Engl. J. Med., 324, 450–454.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×